Skip to content
Research report | 6/9/2011

The value of new drugs – a prestudy

6/9/2011 - This report presents a prestudy for an SNS research project running over several years which studies how the value of new drugs can be evaluated from a broad social perspective. One conclusion from the prestudy is that there are good possibilities of obtaining better answers to many of the policy questions that are being asked within drug policy, for example about prescription and the public subsidy of new drugs. The extensive Swedish patent registers offer unique possibilities to study the actual, realized value of drugs.

ARE NEW, EXPENSIVE DRUGS PROFITABLE? There has been a gradual increase in the use of drugs in Sweden for many years, while new drugs are becoming increasingly expensive. There is nothing to indicate that there will be a turn in the trend, which means that the costs for drugs might come to constitute an increasingly larger share of the resources of society in the future. What attitude are we to take to an increased use of new, expensive drugs?

SWEDISH REGISTER DATA BASES PROVIDE A UNIQUE POSSIBILITY TO CONDUCT RESEARCH. In the prestudy, three leading Swedish health economists have studied the international literature in the field and made a survey of how the value of drugs can be studied. The extensive Swedish register databases at the individual level offer unique possibilities to study the actual realized value of drugs. The prestudy presents several proposals for how such studies could be designed. The next step in the research program is to carry out such studies. One objective is to obtain measures for the economic value of introducing new drugs.

Researchers and Scientific Directors for the prestudy of the project
PhD KATARINA STEEN CARLSSON, Professor ULF-G GERDTHAM and Professor ULF PERSSON, The Swedish Institute for Health Economics (IHE)

Released June 9 2011

Categories

Subject

Other research report on Health Care

  • Research report Health Care

    Coordinating care of the multimorbid elderly in Sweden – lessons learned from practice and research

    Older patients face medical risks as coordination between municipalities and regions is failing. Clearer central government instructions regarding these types of collaborations are necessary, according to Paula Blomqvist and Ulrika Winblad in a new SNS report.
  • Research report Health Care

    Covid-19 in nursing homes as experienced by employees

    Employees highlight great challenges in nursing homes during the pandemic. Their experiences offer important lessons for the future, according to Sara Erlandsson, Petra Ulmanen and Sara Wittzell in a new SNS report.
  • Research report Health Care

    Reliable Control and Organization of Welfare

    Trust-based governance has been introduced in several Swedish municipalities and regions. However, trust is not something that can be mandated from above, according to six researchers in the fields of work science and business administration in a new SNS report.
  • Research report Health Care

    Measuring the Value of Elderly Care

    Swedish elderly care has undergone significant changes in recent years and is now being developed using new welfare technologies. But is this in line with what the elderly want? Without properly analyzing what the elderly want, this development risks reducing their quality of life, according to researchers Sara Olofsson and Ulf Persson in a new SNS report.

Subscribe to our Newsletter

Stay updated with our latest insights, seminars and research news.